Taysha Gene Therapies' (TSHA) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Taysha Gene Therapies (NASDAQ:TSHA - Free Report) in a research report released on Tuesday,Benzinga reports. Cantor Fitzgerald currently has a $7.00 price target on the stock.

A number of other research firms have also weighed in on TSHA. Chardan Capital reaffirmed a "buy" rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, August 13th. Canaccord Genuity Group lowered their price objective on Taysha Gene Therapies from $7.00 to $6.00 and set a "buy" rating for the company in a research note on Wednesday, August 14th. Finally, Needham & Company LLC restated a "buy" rating and set a $6.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $6.38.

Taysha Gene Therapies Price Performance

Taysha Gene Therapies stock traded up $0.76 during midday trading on Tuesday, reaching $2.39. The company had a trading volume of 24,416,643 shares, compared to its average volume of 2,536,980. The company has a market capitalization of $489.81 million, a P/E ratio of -10.40 and a beta of 0.44. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.22 and a quick ratio of 5.22. Taysha Gene Therapies has a 12-month low of $1.19 and a 12-month high of $4.32. The firm's fifty day simple moving average is $1.97 and its 200-day simple moving average is $2.39.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.01. The firm had revenue of $1.11 million for the quarter, compared to the consensus estimate of $3.62 million. Taysha Gene Therapies had a negative net margin of 888.18% and a negative return on equity of 168.91%. During the same period in the previous year, the firm posted ($0.38) earnings per share. As a group, equities analysts anticipate that Taysha Gene Therapies will post -0.35 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Creative Planning purchased a new stake in Taysha Gene Therapies in the 3rd quarter worth about $28,000. Principal Financial Group Inc. purchased a new position in shares of Taysha Gene Therapies during the second quarter worth $48,000. China Universal Asset Management Co. Ltd. increased its position in Taysha Gene Therapies by 79.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company's stock valued at $79,000 after acquiring an additional 17,446 shares during the period. Intech Investment Management LLC acquired a new stake in shares of Taysha Gene Therapies during the 3rd quarter worth $85,000. Finally, Scientech Research LLC acquired a new position in shares of Taysha Gene Therapies during the second quarter valued at approximately $97,000. 77.70% of the stock is owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.